GRIA1 and schizophrenia: Post-mortem studies have also demonstrated that GluA1 protein and mRNA expression are decreased in patients with schizophrenia (e.g. [11–15], which are unlikely to be attributed to long term neuroleptic treatment e.g. [16–19]).